Skip to main content
All lobbying clients

ALEXION PHARMACEUTICALS, INC.

Lobbying client · Massachusetts · filed 2025 to 2026

Rare Disease Pharmaceutical company.

$1,025,000 Reported spend
28 Filings counted
5 Outside firms hired
5 Bills named

Spend is reported income plus in-house expenses across 28 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 5 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as ALEXION PHARMACEUTICALS.

 Who filed for this client 5

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 5
  • H.R. 946
    ORPHAN Cures Act
    6 filings
  • H.R. 1672
    Maintaining Investments in New Innovation Act
    2 filings
  • S. 864
    HELP Copays Act
    2 filings
  • H.R. 5539
    ORPHAN Cures Act
    1 filing
  • S. 3131
    ORPHAN Cures Act
    1 filing
 Reported by year 2 years
  • 2026 $360,000 9 filings
  • 2025 $665,000 19 filings
 Issues lobbied 2

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 5
  • HOUSE OF REPRESENTATIVES 21
  • SENATE 21
  • Centers For Medicare and Medicaid Services (CMS) 2
  • Health & Human Services, Dept of (HHS) 2
  • White House Office 2
 Recent filings 29 total
Q3 report
FEROX STRATEGIES
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 19, 2026
View → Q3 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $10,000 income · posted Oct 18, 2026
View → Q3 report
FORBES-TATE
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 18, 2026
View → Q2 report
FORBES-TATE
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View → Q2 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $10,000 income · posted Jul 20, 2026
View → Q2 report
FEROX STRATEGIES
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View → Q1 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $10,000 income · posted Apr 20, 2026
View → Q1 report
FORBES-TATE
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 17, 2026
View → Q1 report
FEROX STRATEGIES
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 17, 2026
View → Q4 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $10,000 income · posted Jan 20, 2026
View → Q4 report
FEROX STRATEGIES
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $60,000 income · posted Jan 20, 2026
View → Q4 terminationNo activity
MANATT, PHELPS, AND PHILLIPS
4th Quarter 2025 (Oct 1 - Dec 31) · posted Jan 20, 2026
View → Q4 report
FORBES-TATE
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 17, 2026
View → Q3 report
FEROX STRATEGIES
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2025
View → Q3 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $10,000 income · posted Oct 20, 2025
View → Q3 report
FORBES-TATE
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 19, 2025
View → Q3 report
MANATT, PHELPS, AND PHILLIPS
3rd Quarter 2025 (July 1 - Sep 30) · $15,000 income · posted Oct 16, 2025
View → Q2 termination
TODD STRATEGY GROUP
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Oct 14, 2025
View → Q2 reportNo activity
JEFFREY J. KIMBELL & ASSOCIATES, INC.
2nd Quarter 2025 (Apr 1 - June 30) · posted Jul 21, 2025
View → Q2 report
TODD STRATEGY GROUP Amended
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 19, 2025
View →

Showing the 20 most recent of 29 filings. Search the explorer for "ALEXION PHARMACEUTICALS, INC.".

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem